Table 1. Patient and tumor characteristics.
| Clinical characteristics | N (%) |
|---|---|
| Total | 456 (100.0) |
| Age (years), mean ± SD | 55.2±11.4 |
| <50 | 148 (32.5) |
| ≥50 | 308 (67.5) |
| Laterality | |
| Left | 226 (49.6) |
| Right | 230 (50.4) |
| Tumor size (cm), mean ± SD | 1.7±1.0 |
| Tumor localization | |
| Multicentric | 156 (34.2) |
| Superior (external/internal/central) | 111/50/41 (24.3/11.0/9.0) |
| Inferior (external/internal/central) | 22/23/10 (4.8/5.0/2.2) |
| Midline (external/internal) | 20/10 (4.4/2.2) |
| Areolar or retro-areolar | 13 (2.6) |
| Bloom score | |
| 1 | 144 (31.6) |
| 2 | 180 (39.5) |
| 3 | 93 (20.4) |
| UNK | 39 (8.6) |
| Cancer type | |
| Ductal carcinoma | 374 (82.0) |
| Lobular carcinoma | 66 (14.5) |
| Others* | 16 (3.5) |
| Type of surgery | |
| Mastectomy | 159 (34.9) |
| Breast conservative surgery | 297 (65.1) |
| Estrogen receptor (ER) | |
| ER positive | 397 (87.1) |
| ER negative | 57 (12.5) |
| UNK | 2 (0.4) |
| Progesterone receptor (PR) | |
| PR positive | 144 (31.6) |
| PR negative | 310 (68.0) |
| UNK | 2 (0.4) |
| HER 2 status | |
| HER2 amplified | 66 (14.5) |
| HER2 negative | 390 (85.5) |
*, tubular carcinoma, canalicular-lobular carcinoma, carcinoma canalicular infiltrant, mucinous carcinoma, tubulolobular carcinoma, papillary carcinoma, colloidal carcinoma, micropapillary canalicular carcinoma, adenosquamous carcinoma. UNK, unknown; HER2, human epithelial growth factor receptor 2.